Sorrento Therapeutics ( ) - 株価, ニュースと分析DB:8STN

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

8STN 株式概要

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain.

会社概要

8STN ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	0/6
配当金	0/6

報酬

リスク分析

過去5年間で収益は年間31.2%減少しました。

マイナスの株主資本

株式の流動性は非常に低い

キャッシュランウェイが1年未満である

+1 さらなるリスク

Sorrento Therapeutics, Inc. 競合他社

Heidelberg Pharma

XTRA:HPHA

€112.3m

Formycon

XTRA:FYB

€937.6m

2invest

XTRA:2INV

€60.4m

Biotest

XTRA:BIO3

€1.3b

価格と性能

の歴代最高値、変動、値下がりまとめSorrento Therapeutics
過去の株価
現在の株価	US$0.30
52週高値	US$2.79
52週安値	US$0.13
ベータ	2.12
11ヶ月の変化	0%
3ヶ月変化	19.20%
1年変化	-80.28%
33年間の変化	-91.94%
5年間の変化	-95.22%
IPOからの変化	-94.92%

Recent updates

株主還元

	8STN	DE Biotechs	DE 市場
7D	0%	2.6%	4.5%
1Y	-80.3%	-16.4%	13.4%

業界別リターン: 8STN過去 1 年間で-22.4 % の収益を上げたGerman Biotechs業界を下回りました。

リターン対市場: 8STNは、過去 1 年間で2.4 % のリターンを上げたGerman市場を下回りました。

価格変動

Is 8STN's price volatile compared to industry and market?
8STN volatility
8STN Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.3%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.8%
10% least volatile stocks in DE Market	2.4%

安定した株価: 8STNの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: 過去 1 年間の8STNのボラティリティの変化を判断するにはデータが不十分です。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2006	949	Henry Ji	www.sorrentotherapeutics.com

Sorrento Therapeutics, Inc. 基礎のまとめ

Sorrento Therapeutics の収益と売上を時価総額と比較するとどうか。
8STN 基礎統計学
時価総額	€154.45m
収益（TTM）	-€626.04m
売上高(TTM)	€56.58m

2.7x

P/Sレシオ

-0.2x

PER（株価収益率

8STN は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
8STN 損益計算書（TTM）
収益	US$60.71m
売上原価	US$233.93m
売上総利益	-US$173.23m
その他の費用	US$498.42m
収益	-US$671.64m

直近の収益報告

Mar 31, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-1.24
グロス・マージン	-285.36%
純利益率	-1,106.41%
有利子負債／自己資本比率	-55.7%

8STN の長期的なパフォーマンスは？

過去の実績と比較を見る

8STN 株式概要

報酬

リスク分析

Sorrento Therapeutics, Inc. 競合他社

XTRA:HPHA

€112.3m

XTRA:FYB

€937.6m

XTRA:2INV

€60.4m

XTRA:BIO3

€1.3b

価格と性能

最新ニュース

Final DIP Financing Approved for Sorrento Therapeutics, Inc.

Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors

Sorrento Therapeutics, Inc. Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee Patients

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Recent updates

Final DIP Financing Approved for Sorrento Therapeutics, Inc.

Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors

Sorrento Therapeutics, Inc. Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee Patients

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R Mzl)

Sorrento Therapeutics, Inc. Announces Full Enrollment of Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), Second Generation Oral Mpro Inhibitor, as Standalone Treatment for COVID-19

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Therapeutics, Inc.(NasdaqCM:SRNE) dropped from S&P Biotechnology Select Industry Index

Sorrento Therapeutics Received Written Notice from the Staff of The Nasdaq Stock Market LLC

Sorrento Therapeutics, Inc., Annual General Meeting, Apr 06, 2023

Sorrento Therapeutics, Inc. Releases Unblinded Phase 1B Study Data of Its Oral Main Viral Protease Inhibitor, OVYDSO™ (STI-1558) in Covid Patients

Sorrento Therapeutics Receives FDA Clearance to Initiate Clinical Trials with A Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus

Sorrento Therapeutics, Inc. Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented At Asian Congress of the European Society for Medical Oncology (Esmo)

Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from A Phase IB Study in China with STI-1558

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.20 loss per share (vs US$0.40 loss in 3Q 2021)

Less than half of directors are independent

Sorrento Therapeutics, Inc., Annual General Meeting, Dec 15, 2022

Sorrento Therapeutics, Inc. Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with Sti-1558, an Oral Mpro Inhibitor as A Standalone Oral Treatment and Prevention of Covid-19 Without the Need for A Ritonavir Booster

Sorrento Therapeutics, Inc. Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Improvements in Rheumatoid Arthritis Disease Measures At 50% of the Standard Dose for Patients (7 of 7) with an Inadequate Response to Subcutaneous Injections

Sorrento Therapeutics, Inc. Announces Significant Positive Pivotal Trial Results as Assessed by an Independent Review Committee (IRC) With Matured Long-Term (Over Three Years) Follow-Up Data of Abivertinib for the Treatment of Advanced Non-Small Cell Lung Cancer

Sorrento Therapeutics, Inc. Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Therapeutics, Inc. Announces the Completion of the SAD Portion of the Phase 1 Study of Its Oral Main Viral Protease (Mpro) Inhibitor, the STI-1558

Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19

Sorrento Therapeutics, Inc. Announces First Subject Dosed in A Phase I Clinical Study of Sti-1558, an Oral Mpro Inhibitor as A Standalone Treatment and Prevention of Covid-19 Without Co-Administration of Ritonavir Booster

Less than half of directors are independent

Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors

Sorrento Therapeutics, Inc. Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)

Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern

Sorrento Therapeutics, Inc. Announces That It Has Received Clearance from the FDA for Its Investigational New Drug Application for Intravenous (Iv) Sti-9167

Sorrento Therapeutics Announces the Appointment of Laura Hamill to Its Board of Directors

Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients with Severe Pneumonia Due to Covid-19

Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure

Sorrento Therapeutics, Inc. announced delayed annual 10-K filing

Sorrento Therapeutics, Inc Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses

Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) acquired an unknown majority stake in Zhengzhou Fortune Bioscience Co., Ltd..

Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) completed the acquisition of Virex Health, Inc.

Sorrento Announces its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron

Sorrento Therapeutics, Inc. Announces Covishield (STI-9167), A Broad-Spectrum Neutralizing Antibody, Potently Neutralizes Omicron and Omicron (+R346K) Variants of Sars-Cov-2

Sorrento Therapeutics, Inc. Announces Completion of Enrollment in US Phase 2 Clinical Trial for Covi-Drops and Achievement of Interim Analysis Threshold in the UK

Brazilian Health Regulatory Agency Authorizes Sorrento Therapeutics, Inc.'s Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler)

Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors

Sorrento Therapeutics, Inc. Begins Enrollment in Phase 2 Trial of Resiniferatoxin for the Treatment of Pain Due to Knee Osteoarthritis (OA)

Sorrento Announces Publication of Series of Novel Sars-Cov-2 Main Protease (Mpro) Inhibitors for Potential Treatment of Covid-19 Patients Infected with Sars-Cov-2 Variants of Concern, Including Omicron

Insufficient new directors

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.33 loss in 3Q 2020)

Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX as Compared to a Globally Leading Rapid Antigen Test

Sorrento Therapeutics, Inc. Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients

Sorrento Therapeutics, Inc. Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device

Sorrento Therapeutics, Inc. Publishes Positive Initial Results of Sofusa® Lymphatic Drug Delivery System in A Phase 1B Rheumatoid Arthritis Study Using Enbrel

Sorrento Announces its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern

Sorrento Therapeutics, Inc. Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.57 loss per share (vs US$0.36 loss in 2Q 2020)